Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Journal of Chemotherapy (Florence, Italy)
|
October 21, 2024
Comparative efficacy of chemo-immunotherapy combination regimens in the frontline setting for NSCLC based on reconstructed patient data
Andrea Ossato, Luna Del Bono, Lorenzo Gasperoni, et al.
Cancers
|
February 10, 2024
Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival
Andrea Ossato, Lorenzo Gasperoni, Luna Del Bono, et al.
Oncology Research
|
June 26, 2026
Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data
Lorenzo Gasperoni, Luna Del Bono, Alberto Farolfi, et al.
Cancers
|
June 26, 2026
Comparative Efficacy of First-Line Therapeutic Options for ES-SCLC: An Indirect Comparison Using IPDfromKM-Reconstructed Individual Patient Data
Lorenzo Gasperoni, Tiziano Lupi, Luna Del Bono, et al.
Current Oncology (Toronto, Ont.)
|
January 24, 2025
Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials
Andrea Messori, Andrea Ossato, Lorenzo Gasperoni, et al.
Cancers
|
July 13, 2024
A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?
Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, et al.
Cancers
|
November 27, 2025
Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based Regimens
Lorenzo Gasperoni, Luca Cancanelli, Andrea Ossato, et al.
Frontiers in Pharmacology
|
September 15, 2025
Tracking a decade of phase I clinical trials in Italy: trends and insights from national and european registries amid regulatory change
Eleonora De Paola, Luna Del Bono, Diego Alejandro Dri, et al.
Translational Lung Cancer Research
|
June 15, 2026
Long-term outcomes of ALK inhibitors in metastatic <i>ALK</i>-positive non-small cell lung cancer: an updated indirect comparison using reconstructed patient-level data
Andrea Ossato, Vera Damuzzo, Luna Del Bono, et al.
Frontiers in Oncology
|
May 25, 2026
Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Journal of Chemotherapy (Florence, Italy)
|
October 21, 2024
Comparative efficacy of chemo-immunotherapy combination regimens in the frontline setting for NSCLC based on reconstructed patient data
Andrea Ossato, Luna Del Bono, Lorenzo Gasperoni, et al.
Cancers
|
February 10, 2024
Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival
Andrea Ossato, Lorenzo Gasperoni, Luna Del Bono, et al.
Oncology Research
|
June 26, 2026
Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data
Lorenzo Gasperoni, Luna Del Bono, Alberto Farolfi, et al.
Cancers
|
June 26, 2026
Comparative Efficacy of First-Line Therapeutic Options for ES-SCLC: An Indirect Comparison Using IPDfromKM-Reconstructed Individual Patient Data
Lorenzo Gasperoni, Tiziano Lupi, Luna Del Bono, et al.
Current Oncology (Toronto, Ont.)
|
January 24, 2025
Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials
Andrea Messori, Andrea Ossato, Lorenzo Gasperoni, et al.
Cancers
|
July 13, 2024
A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?
Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, et al.
Cancers
|
November 27, 2025
Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based Regimens
Lorenzo Gasperoni, Luca Cancanelli, Andrea Ossato, et al.
Frontiers in Pharmacology
|
September 15, 2025
Tracking a decade of phase I clinical trials in Italy: trends and insights from national and european registries amid regulatory change
Eleonora De Paola, Luna Del Bono, Diego Alejandro Dri, et al.
Translational Lung Cancer Research
|
June 15, 2026
Long-term outcomes of ALK inhibitors in metastatic <i>ALK</i>-positive non-small cell lung cancer: an updated indirect comparison using reconstructed patient-level data
Andrea Ossato, Vera Damuzzo, Luna Del Bono, et al.
Frontiers in Oncology
|
May 25, 2026
Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, et al.
Page
of 2